This 2021 edition of Reported Tuberculosis in the United States reflects ongoing challenges facing the public health and tuberculosis (TB) communities. The report describes information on cases of TB disease reported to CDC since 1993. This year’s report emphasizes cases counted by the reporting areas in 2021 and the ongoing effects of the COVID-19 pandemic on TB surveillance.
This report, which marks World AIDS Day 2022, unpacks the impact that inequalities have had on the AIDS response.
This report, which marks World AIDS Day 2022, unpacks the impact that inequalities have had on the AIDS response.
This report, which marks World AIDS Day 2022, unpacks the impact that inequalities have had on the AIDS response.
This report, which marks World AIDS Day 2022, unpacks the impact that inequalities have had on the AIDS response.
This report, which marks World AIDS Day 2022, unpacks the impact that inequalities have had on the AIDS response.
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This report is updated annually.
This document discusses how an estimated 2.4 million people in the U.S. are living with hepatitis C infection, while up to 1.59 million people could be living with hepatitis B in the U.S. The need for expanded, standardized, and reliable viral hepatitis surveillance continues to impact public health efforts, resources, and response across the U.S. to this epidemic.
The landscape of treatment for hepatitis C virus (HCV) infection has evolved substantially since the introduction of highly effective HCV protease inhibitor therapies in 2011. The pace of change has increased rapidly as numerous new drugs with different mechanisms of action have become available over the past few years.
The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV.
